Bristol-Myers Squibb Company (BMY)vsEquinix Inc (EQIX)
BMY
Bristol-Myers Squibb Company
$60.59
+5.21%
HEALTHCARE · Cap: $123.71B
EQIX
Equinix Inc
$1,082.83
-0.57%
REAL ESTATE · Cap: $106.79B
Smart Verdict
WallStSmart Research — data-driven comparison
Bristol-Myers Squibb Company generates 420% more annual revenue ($48.19B vs $9.26B). EQIX leads profitability with a 14.6% profit margin vs 14.6%. EQIX appears more attractively valued with a PEG of 4.91. BMY earns a higher WallStSmart Score of 62/100 (C+).
BMY
Buy62
out of 100
Grade: C+
EQIX
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+31.8%
Fair Value
$87.81
Current Price
$60.59
$27.22 discount
Margin of Safety
-38.5%
Fair Value
$626.41
Current Price
$1082.83
$456.42 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 40 in profit
Earnings expanding 1392.0% YoY
Large-cap with strong market position
Attractively priced relative to earnings
Strong operational efficiency at 28.2%
Generating 1.6B in free cash flow
Large-cap with strong market position
Strong operational efficiency at 21.5%
Earnings expanding 22.9% YoY
Areas to Watch
1.3% revenue growth
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, EPS Growth, Market Cap.
Bull Case : EQIX
The strongest argument for EQIX centers on Market Cap, Operating Margin, EPS Growth.
Bear Case : BMY
The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : EQIX
The primary concerns for EQIX are Debt/Equity, Piotroski F-Score, PEG Ratio. A P/E of 74.6x leaves little room for execution misses. Debt-to-equity of 1.61 is elevated, increasing financial risk.
Key Dynamics to Monitor
EQIX carries more volatility with a beta of 1.00 — expect wider price swings.
EQIX is growing revenue faster at 8.1% — sustainability is the question.
BMY generates stronger free cash flow (1.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BMY scores higher overall (62/100 vs 50/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →Equinix Inc
REAL ESTATE · REIT - SPECIALTY · USA
Equinix, Inc. is an American multinational company headquartered in Redwood City, California, that specializes in Internet connection and data centers.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?